Bio-Techne Corp.: Q3 FY2026 earnings call

What management said about Q3 FY2026, from the documents filed with the SEC on 6 May 2026: press release. The quarter’s numbers.

Read the filing

Key takeaways

• Revenue declined 2% this quarter: Net sales were $311.4 million, down 2%. Organic revenue also fell 2%, weighed by prior-year GMP fast-track orders and timing of large Commercial Supply shipments. Source
• GAAP EPS up, adjusted EPS down: Diluted GAAP EPS was $0.32 against $0.14. Adjusted EPS was $0.53, compared with $0.56 a year earlier. Source
• Protein Sciences sales dipped 1%: Protein Sciences net sales were $226.2 million, down 1% from $227.7 million a year earlier. Source
• Growth vectors grew in several lines: Proteomic Analysis instruments grew mid-single digits, Spatial Biology grew mid-teens, and GMP proteins excluding fast-track customers grew nearly 50%. Source
• Large pharma led, biotech lagged: Large pharma grew double digits for a sixth consecutive quarter. Emerging biotech spending continued to lag, while U.S. academic markets grew low single digits. Source
• Adjusted margin fell to 34.2%: Adjusted operating margin was 34.2%, against 34.9% in the prior-year quarter. Source

“While biotech funding remains healthy, it has not yet translated into broad-based demand across our portfolio.”

Kim Kelderman, President and Chief Executive Officer of Bio-Techne

Results and growth drivers

• Revenue declined 2% this quarter: Net sales were $311.4 million, down 2%. Organic revenue also fell 2%, weighed by prior-year GMP fast-track orders and timing of large Commercial Supply shipments. Source
• GAAP EPS up, adjusted EPS down: Diluted GAAP EPS was $0.32 against $0.14. Adjusted EPS was $0.53, compared with $0.56 a year earlier. Source
• GAAP operating income rose 95%: GAAP operating income rose to $75.5 million from $38.7 million. The company cited the Exosome Diagnostics divestiture, profitability initiatives and a prior-year non-recurring arbitration payment. Source
• Prior quarter revenue was flat: The prior quarter reported revenue of $295.9 million, with reported and organic growth flat to the prior year.

Segments and regions

• Protein Sciences sales dipped 1%: Protein Sciences net sales were $226.2 million, down 1% from $227.7 million a year earlier. Source
• Protein Sciences organic revenue fell 4%: Organic revenue for the segment decreased 4%, with foreign currency exchange adding 3%. Source
• Protein Sciences margin eased to 44.2%: Segment operating margin was 44.2%, against 45.6% a year earlier. Source
• Diagnostics and Spatial Biology sales fell 4%: Segment net sales were $85.6 million, down 4% from $89.2 million a year earlier. Source
• Diagnostics margin rose to 12.1%: Segment operating margin was 12.1%, against 9.4%. Management attributed the increase to the Exosome Diagnostics divestiture and profitability initiatives, partly offset by product mix. Source

“We are encouraged by early indicators pointing to a more constructive outlook as funding activity and customer purchasing begin to realign.”

Kim Kelderman, President and Chief Executive Officer of Bio-Techne

Products, customers and demand

• Growth vectors grew in several lines: Proteomic Analysis instruments grew mid-single digits, Spatial Biology grew mid-teens, and GMP proteins excluding fast-track customers grew nearly 50%. Source
• Large pharma led, biotech lagged: Large pharma grew double digits for a sixth consecutive quarter. Emerging biotech spending continued to lag, while U.S. academic markets grew low single digits. Source
• Biotech funding not yet broad demand: Management said biotech funding remains healthy but has not yet produced broad-based demand across the portfolio. Source
• Early signs of realignment: Management is encouraged by early indicators that funding activity and customer purchasing are beginning to realign. Source

Costs, margins and profitability

• Adjusted margin fell to 34.2%: Adjusted operating margin was 34.2%, against 34.9% in the prior-year quarter. Source
• Volume and mix weighed on margin: Management attributed the adjusted margin change to volume and product mix, partly offset by profitability initiatives and the Exosome Diagnostics divestiture. Source
• GAAP margin helped by initiatives: Management cited profitability initiatives, the Exosome Diagnostics divestiture and a prior-year arbitration payment as favorable to GAAP margin, with product mix unfavorable. Source
• R&D expense declined: R&D expense was $23.5 million in the quarter, against $24.6 million a year earlier. Nine-month R&D was $70.8 million, against $73.5 million. Source

“The Bio-Techne team delivered solid execution amid a mixed end-market environment,”

Kim Kelderman, President and Chief Executive Officer of Bio-Techne

Cash, capital and shareholder returns

• Nine-month operating cash flow rose: Net cash from operating activities was $196.7 million for nine months, against $189.4 million a year earlier. Source
• Cash balance rose since June: Cash and equivalents were $209.8 million at March 31, 2026, against $162.2 million at June 30, 2025. Source
• Long-term debt reduced to $200 million: Long-term debt obligations were $200.0 million, against $346.0 million at June 30, 2025. Source
• Capital spending lower year on year: Additions to property and equipment were $20.4 million for nine months, against $26.1 million a year earlier. Source
• Buybacks minimal; dividends paid: Repurchases of common stock were $24 thousand for nine months, against $175.7 million a year earlier. Cash dividends were $37.4 million, against $38.0 million. Source

Strategy and portfolio

• Portfolio spans the scientific journey: Management said the portfolio is organized to support durable, high-value applications from discovery through precision diagnostics. Source
• Operating discipline and flexibility cited: Management linked operating discipline and financial flexibility to its view that Bio-Techne remains positioned for long-term value. Source
• Held-for-sale Diagnostics business excluded: A Diagnostics and Spatial Biology business met held-for-sale criteria at June 30, 2025, and is excluded from fiscal 2026 segment results. Source

Coming up, as management said on 6 May 2026

• Funding and purchasing expected to realign: Management is encouraged by early indicators that funding and customer purchasing are beginning to realign. No timing was given. Source

Figures management reported

Risks management discussed

• Demand: Emerging biotech spending continued to lag, and biotech funding has not yet translated into broad demand across the portfolio. Source
• Demand: Revenue faced a comparison against prior-year GMP fast-track orders, which management cited as a drag this quarter. Source
• Operational: Timing of large Commercial Supply shipments weighed on this quarter's revenue. Source
• Financial: Unfavorable volume and product mix pressured adjusted operating margin, which fell to 34.2% from 34.9%. Source
• External: Management described the end-market environment as mixed. Source

Other quarters

• Q4 FY2026 earnings call
• Q2 FY2026 earnings call
• Q1 FY2026 earnings call
• Q4 FY2025 results

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.